UK Markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
110.54+0.91 (+0.83%)
At close: 04:00PM EDT
106.00 -4.54 (-4.11%)
After hours: 05:18PM EDT

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees840

Key executives

NameTitlePayExercisedYear born
Mr. Douglas S. Ingram Esq.Pres, CEO & Director1.55MN/A1963
Mr. Ian Michael EstepanExec. VP & CFO861.75kN/A1976
Mr. William F. CiambroneExec. VP of Technical Operations780.28kN/A1964
Dr. Louise R. Rodino-Klapac Ph.D.Exec. VP, Chief Scientific Officer and Head of R&D929.68kN/A1978
Mr. Ryan E. BrownSr. VP, Gen. Counsel & Corp. Sec.913.64kN/A1978
Mary JenkinsSr. Mang. of Investor RelationsN/AN/AN/A
Ms. Alison NasisiChief People Officer & VPN/AN/AN/A
Dr. Diane L. BerrySr. VP of Global Health Policy and Gov. & Patient AffairsN/AN/AN/A
Mr. Dallan MurraySr. VP & Chief Customer OfficerN/AN/AN/A
Mr. Joseph BraticaController & VPN/AN/A1964
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Sarepta Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2022 is 3. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.